Drug Profile
Etanercept biosimilar - Biocon/Viatris
Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Biocon
- Developer Biocon; Viatris Inc
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in India (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 30 Nov 2017 Etanercept biosimilar is still in preclinical development for Autoimmune disorders in USA and India (Biocon pipeline, November 2017)